ATE335484T1 - Wirkstoffkombination aus cyp2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung - Google Patents

Wirkstoffkombination aus cyp2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung

Info

Publication number
ATE335484T1
ATE335484T1 AT98956735T AT98956735T ATE335484T1 AT E335484 T1 ATE335484 T1 AT E335484T1 AT 98956735 T AT98956735 T AT 98956735T AT 98956735 T AT98956735 T AT 98956735T AT E335484 T1 ATE335484 T1 AT E335484T1
Authority
AT
Austria
Prior art keywords
cyp2a6
individual
nicotine
risk
enzyme
Prior art date
Application number
AT98956735T
Other languages
German (de)
English (en)
Inventor
Edward M Sellers
Rachel F Tyndale
Original Assignee
Nicogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27490603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE335484(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicogen Inc filed Critical Nicogen Inc
Application granted granted Critical
Publication of ATE335484T1 publication Critical patent/ATE335484T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
AT98956735T 1997-12-01 1998-12-01 Wirkstoffkombination aus cyp2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung ATE335484T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6702197P 1997-12-01 1997-12-01
US6702097P 1997-12-01 1997-12-01
US8484798P 1998-05-08 1998-05-08
US10739298P 1998-11-06 1998-11-06

Publications (1)

Publication Number Publication Date
ATE335484T1 true ATE335484T1 (de) 2006-09-15

Family

ID=27490603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956735T ATE335484T1 (de) 1997-12-01 1998-12-01 Wirkstoffkombination aus cyp2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung

Country Status (12)

Country Link
EP (1) EP1033979B2 (enExample)
JP (1) JP2001524516A (enExample)
CN (1) CN100362995C (enExample)
AT (1) ATE335484T1 (enExample)
AU (1) AU762671C (enExample)
BR (1) BR9815128A (enExample)
CA (1) CA2312851A1 (enExample)
DE (1) DE69835534T3 (enExample)
ES (1) ES2273441T5 (enExample)
NZ (1) NZ505439A (enExample)
PT (1) PT1033979E (enExample)
WO (1) WO1999027919A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900490D0 (sv) * 1999-02-15 1999-02-15 A & Science Invest Ab Diagnostic agent and method
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
CN1308462C (zh) * 2003-09-22 2007-04-04 周宏灏 个体化用药基因型诊断芯片及其制造方法和应用方法
KR100829122B1 (ko) * 2006-12-05 2008-05-13 한국과학기술연구원 당귀 추출물 또는 이로부터 분리한 쿠마린계 화합물을 유효성분으로 함유하는 폐암 예방용 조성물
EP2031072A1 (en) * 2007-08-27 2009-03-04 Andreas Ziegler Method for in-vitro diagnosing a predisposition to smoking and a pharmaceutical composition for treating tobacco abuse
JP5275060B2 (ja) * 2009-01-30 2013-08-28 学校法人近畿大学 Ｃｙｐ２ａ６阻害剤及びｃｙｐ２ａ６阻害活性物質のスクリーニング方法
CN104004852B (zh) * 2014-06-17 2015-12-02 陕西佰美基因股份有限公司 一种基于荧光定量pcr检测cyp2a6全基因缺失的方法
EP3157519B1 (en) 2014-06-19 2021-05-12 Immunolight, LLC Methods and systems for treating cell proliferation disorders with psoralen derivatives
EP3207924A1 (de) 2016-02-17 2017-08-23 Flaxan GmbH & Co. KG Pharmazeutische zubereitung zur hemmung humaner cyp-enzyme
CN116183779B (zh) * 2023-04-18 2025-01-24 云南省烟草农业科学研究院 基于一步净化和液相色谱-串联质谱的烟气中TSNAs测定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066998C1 (ru) * 1992-06-25 1996-09-27 Валерий Иванович Вольвич Способ получения средства для лечения вирусного гепатита а
WO1995034679A2 (en) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism
DE19646977A1 (de) * 1995-09-29 1998-01-15 Schwabe Willmar Gmbh & Co Stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen
EP0954304A2 (en) † 1996-07-17 1999-11-10 Nicogen Inc. Methods for regulating nicotine metabolism

Also Published As

Publication number Publication date
JP2001524516A (ja) 2001-12-04
ES2273441T5 (es) 2010-06-28
AU1328699A (en) 1999-06-16
CN1299276A (zh) 2001-06-13
EP1033979B2 (en) 2010-02-24
CN100362995C (zh) 2008-01-23
PT1033979E (pt) 2006-12-29
EP1033979A2 (en) 2000-09-13
CA2312851A1 (en) 1999-06-10
EP1033979B9 (en) 2007-02-28
AU762671C (en) 2004-11-18
DE69835534D1 (de) 2006-09-21
BR9815128A (pt) 2000-10-10
ES2273441T3 (es) 2007-05-01
WO1999027919A2 (en) 1999-06-10
AU762671B2 (en) 2003-07-03
WO1999027919A3 (en) 1999-08-12
NZ505439A (en) 2005-02-25
EP1033979B1 (en) 2006-08-09
DE69835534T3 (de) 2010-09-23
DE69835534T2 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
Tyndale et al. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk
Sato et al. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes
Seitz et al. Alcohol and cancer
Strasser et al. An association of CYP2A6 genotype and smoking topography
Liu et al. Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco (endo) plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump
Nakajima et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
Saha et al. Cigarette smoke and adverse health effects: An overview of research trends and future needs
ATE335484T1 (de) Wirkstoffkombination aus cyp2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung
Xu et al. CYP2A6 genetic variation and potential consequences
Nebert et al. The evolution of drug metabolism
Tan et al. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population
Hirvonen et al. The human CYP2E1 gene and lung cancer: Dra I and Rsa I restriction fragment length polymorphisms in a Finish study population
Tyndale et al. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior
Prass et al. Hyperbaric oxygenation induced tolerance against focal cerebral ischemia in mice is strain dependent
Sikdar et al. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users
Lewis et al. Polymorphisms in the NAD (P) H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population
Worrall et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6
Sellers et al. Mimicking gene defects to treat drug dependence
Raz et al. Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity
Kiyohara et al. Genetic polymorphisms and environmental risk of lung cancer: a review
Gu et al. Intraperitoneal administration of coumarin causes tissue-selective depletion of cytochromes P450 and cytotoxicity in the olfactory mucosa
Chen et al. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China
Tyndale et al. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption
Laforest et al. CYP2D6 gene polymorphism in Caucasian smokers: lung cancer susceptibility and phenotype–genotype relationships
Christiani Smoking and the molecular epidemiology of lung cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033979

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1033979

Country of ref document: EP